Health Trials

About this trial

The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by immunomodulatory drugs in combination with glucocorticoids. Moreover, the clinical outcome of MM is supposed to be correlated to the risk of thrombosis. At the biological level, a number of hemostasis abnormalities participate in increasing VTE incidence. Yet, data on predictive biomarkers linked to VTE are limited.

Eligibility criteria

Qualifiers

Patient affiliated to a social security regimen or beneficiary of the same

Signed written informed consent form

Confirmed diagnosis of de novo multiple myeloma, non-previously treated and requiring treatment.

Disqualifiers

Pregnant women

Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent

Refusing participation

Patient whose follow-up or life expectancy is less than 6 months.

Trial design

Treatments tested in this trial

  • Blood samples

Treatment groups

70 Participants
are divided into 1 treatment group

Locations

2
Hospices Civils de Lyon69495, Lyon France
CHU de Saint-Etienne42055, Saint-Etienne France

Sponsors and collaborators

Centre Hospitalier Universitaire de Saint Etienne

Lead sponsor

Source ClinicalTrials.gov